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The Rho family of GTPases plays a major role in the organization of the actin cytoskeleton. These G proteins
are activated by guanine nucleotide exchange factors that stimulate the exchange of bound GDP for GTP. In
their GTP-bound state, these G proteins interact with downstream effectors. Vav2 is an exchange factor for Rho
family GTPases. It is a ubiquitously expressed homologue of Vav1, and like Vav1, it has previously been shown
to be activated by tyrosine phosphorylation. Because Vav1 becomes tyrosine phosphorylated and activated
following integrin engagement in hematopoietic cells, we investigated the tyrosine phosphorylation of Vav2 in
response to integrin-mediated adhesion in fibroblasts and epithelial cells. However, no tyrosine phosphoryla-
tion of Vav2 was detected in response to integrin engagement. In contrast, treating cells with either epidermal
growth factor or platelet-derived growth factor stimulated tyrosine phosphorylation of Vav2. We have examined
the effects of overexpressing either wild-type or amino-terminally truncated (constitutively active) forms of
Vav2 as fusion proteins with green fluorescent protein. Overexpression of either wild-type or constitutively
active Vav2 resulted in prominent membrane ruffles and enhanced stress fibers. These cells revealed elevated
rates of cell migration that were inhibited by expression of dominant negative forms of Rac1 and Cdc42. Using
a binding assay to measure the activity of Rac1, Cdc42, and RhoA, we found that overexpression of Vav2
resulted in increased activity of each of these G proteins. Expression of a carboxy-terminal fragment of Vav2
decreased the elevation of Rac1 activity induced by epidermal growth factor, consistent with Vav2 mediating
activation of Rac1 downstream from growth factor receptors.
The Rho family of GTP-binding proteins regulates many
important cellular processes, such as cell migration, the orga-
nization of the cytoskeleton, cell-matrix and cell-cell adhesion,
cell cycle progression, and gene expression (22, 44, 50). At
present, 14 members of the Rho family have been identified in
mammalian cells (55), but most attention has been directed
towards three widely expressed members, RhoA, Rac1, and
Cdc42. These three proteins have both unique and overlapping
functions. In terms of cell migration and cytoskeletal organi-
zation, they regulate distinct processes: Cdc42 controls the
assembly of filopodia (28, 33), Rac1 stimulates the formation
of lamellipodia and membrane ruffles (42), and RhoA regu-
lates the assembly of stress fibers (41). Like other G proteins,
Rho family members act as molecular switches and are active
with GTP bound and inactive with GDP bound. The switch
between these states is regulated by guanine nucleotide ex-
change factors (GEFs), which exchange GDP for GTP, and by
GTPase activating proteins (GAPs), which stimulate the en-
dogenous GTPase activity of these proteins, resulting in hy-
drolysis of the bound GTP (22, 50). In turn, the activities of
these GEFs and GAPs are regulated by various signaling path-
ways that are initiated by ligand binding to cell surface recep-
tors. Both soluble agents, such as growth factors (24, 35, 41,
42), and extracellular matrix (ECM) proteins (5, 14, 38, 40)
have been shown to activate Rho family members. Some of the
steps in these signaling pathways remain to be elucidated.
Specifically, many of the GEFs that mediate activation of
Cdc42, Rac1, and RhoA downstream from surface receptors
have not been identified.
One of the best characterized GEFs is Vav1, which is re-
stricted in its distribution to hematopoietic cells (8, 9). Vav1
has been shown to act on Rac1, Cdc42, and RhoA in vitro (16,
23, 36, 46). The exchange factor activity of Vav1 is regulated by
tyrosine phosphorylation (16, 23), and numerous studies have
revealed that Vav1 is rapidly tyrosine phosphorylated in re-
sponse to diverse stimuli (reviewed in reference 9). For exam-
ple, Vav1 becomes tyrosine phosphorylated following ligation
of T- and B-cell receptors and in response to many different
cytokines and growth factors binding to their receptors (8, 9).
In several situations, engagement of specific integrins has also
been shown to stimulate Vav1 tyrosine phosphorylation. This
has been observed following antibody ligation of b2 integrins
in human neutrophils (54), following antibody ligation of b1
integrins in myeloid cells (20), and in platelets as they adhere
to fibrinogen via the integrin aIIbb3 or to collagen or fibronec-
tin via b1 integrins (12). Pursuing the pathway from aIIbb3
engagement to Vav1 activation, Miranti and coworkers were
able to reconstitute Vav1 activation in CHO cells by coexpress-
ing aIIbb3, Vav1, and the tyrosine kinase Syk (31). Previous
work had identified Syk as a tyrosine kinase that becomes
rapidly activated in response to aIIbb3 engagement in plate-
lets, independent of the activation of the focal adhesion kinase
(FAK) (15, 18), a tyrosine kinase that is prominently activated
following integrin-mediated adhesion (21, 29). In another
study, expression of Vav1 in CHO cells resulted in its tyrosine
phosphorylation in response to b1 integrin-mediated adhesion.
This was accompanied by increased stress fibers and lamelli-
podia, consistent with Vav1-mediated activation of RhoA and
Rac1 (53).
Due to its hematopoietic cell-specific expression, Vav1 can-
not be responsible for integrin-mediated activation of Rho
family G proteins in other cell types. The discovery of a more
ubiquitously distributed isoform, Vav2 (25, 45), provided a
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candidate GEF that may act downstream from integrins in
nonhematopoietic cells. The objective of this study was to
determine whether Vav2 was tyrosine phosphorylated and con-
sequently activated in response to b1 integrin engagement and
to determine which Rho family members are activated by
Vav2. We found that unlike Vav1, Vav2 is not tyrosine phos-
phorylated following integrin-mediated cell adhesion to ECM.
However, we have found that it is tyrosine phosphorylated in
response to the growth factors epidermal growth factor (EGF)
and platelet-derived growth factor (PDGF). Moreover, expres-
sion of a dominant negative Vav2 construct was found to di-
minish the elevation in Rac1 activity induced by EGF, suggest-
ing that Vav2 contributes to Rac1 activation in response to
growth factor stimulation of cells. Examination of actin cy-
toskeletal structures in cells transfected with an activated form
of Vav2 revealed extensive lamellipodia and membrane ruffles
but also prominent stress fibers. The observed effects on the
cytoskeleton prompted investigation of a role for Vav2 in cell
motility. Cells expressing activated Vav2 exhibited enhanced
motility that could be blocked by dominant negative forms of
Rac1 or Cdc42. These findings indicated that Vav2 may act on
Rac1, Cdc42, and RhoA in vivo. An assay to specifically detect
GTP-bound versions of these proteins confirmed that activated
Vav2 increases the intracellular levels of active Rac1, Cdc42,
and RhoA.
MATERIALS AND METHODS
Mammalian expression vectors. Full-length human Vav2 cDNA was the gen-
erous gift of David Kwiatkowski (25). To generate Vav2 constructs that were
fused with green fluorescent protein (GFP), Vav2 DNA constructs were engi-
neered to contain an EcoRI restriction site at the 59 end and a HindIII restriction
site at the 39 end to allow for directed subcloning into the multiple cloning site
in the mammalian expression vector, pEGFP-N1 (Clontech, Palo Alto, Calif.).
To ligate the N-terminally truncated Vav2 (amino acids [aa] 184 to 878) to the
pEGFP vector, a HindIII-EcoRI fragment was amplified from human Vav2
cDNA with oligonucleotides 59 AAG GTG AAG CTT CAG CGC GCC ATG
ATT AGA TAC 39 and 59 CTG AAT TCG CTG GAT GCC CTC CTC 39 by
PCR using Pfu Turbo polymerase (Stratagene, La Jolla, Calif.). A C-terminal
Vav2 construct (aa 594 to 878) was amplified using oligonucleotides 59 CCC
AAG CTT GGC GCC ATG CAG AAT TAC CAT 39 and 59 CTG AAT TCG
CTG GAT GCC CTC CTC 39. All constructs were designed with a Kozak
sequence and ATG to be in frame with GFP on the pEGFP-N1 vector. All
PCR-generated fragments were sequenced to confirm that no errors were intro-
duced during PCR.
Antibodies. To generate polyclonal antibodies against Vav2, rabbits were im-
munized with recombinant Vav2 proteins fused to glutathione-S-transferase
(GST). To this end, human Vav2 cDNA was used as the template for a PCR that
generated the C-terminal of Vav2, consisting of the Src homology 3 (SH3)-SH2-
SH3 domains (aa 574 to 876). The primers 59 CCC TGG AAT TCC ATC TCT
CCT GCA GAT CTG 39 and 59 TCA CTG AAT TCC CTC CTC TTC TAG
GTA CGT TGA AGG AAA 39 were used. The PCR product (925 bp) was
designed to contain EcoRI restriction sites at both the 39 and 59 end to allow for
subcloning into the bacterial expression vector, pGEX-4T3 (Amersham Phar-
macia Biotechnology, Piscataway, N.J.). The resulting GST-Vav2 (SH3-SH2-
SH3) fusion protein was expressed in Escherichia coli DH5a. After overnight
induction with isopropyl-b-D-thiogalactopyranoside (IPTG) at 25°C, bacteria
were resuspended in Tris-buffered saline (TBS) with 1% Triton X-100 and lysed
by sonication. Fusion proteins were purified by chromatography on glutathione-
Sepharose (Amersham Pharmacia Biotechnology) from clarified bacterial lysates
and concentrated with Centricon concentrators (Amicon Inc., Beverly, Mass.).
Aliquots (0.5 to 1 mg) of fusion protein were used to immunize rabbits. After a
series of immunizations, a high-titer antiserum was obtained that interacted with
Vav2. This rabbit antiserum was used at 1:20,000 for immunoblotting.
Cell culture. NIH 3T3 and BALB/c3T3 fibroblasts were cultured at 37°C with
10% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose,
supplemented with 10% bovine calf serum. CHOK1 and HEK293 cells were
cultured at 37°C with 10 and 5% CO2, respectively, in DMEM supplemented
with 10% fetal bovine serum. All media contained penicillin G (100 U/ml),
streptomycin sulfate (100 mg/ml), and amphotericin B (25 mg/ml). Culture media
for CHO cells contained additional 1 mM MEM nonessential amino acids (Life
Technologies, Grand Island, N.Y.).
Transient transfection. Lipofectamine Plus was obtained from Life Technol-
ogies and used for transfection of NIH 3T3, BALB/c3T3, HEK293, and CHO
cells essentially according to the manufacturer’s instructions. Briefly, 106 cells
were plated on 100-mm-diameter tissue culture dishes 18 to 24 h prior to
transfection. Four micrograms of the various Vav2 DNA constructs or vector
alone and 20 ml of Plus reagent as well as 30 ml of Lipofectamine were added to
each plate in 1.5 ml of DMEM. After 2 h, cells were washed once with DMEM
and cultured in their regular medium. Cells were used for various assays at 24 to
48 h posttransfection.
Migration assay. To assess the migratory behavior of cells transfected with
various Vav2 DNA constructs, we performed migration assays using a Transwell
cell culture chamber containing polycarbonate membrane inserts with 8-mm
pores (Corning Costar Corp., Cambridge, Mass.). The undersides of the porous
membranes were coated with fibronectin at 10 mg/ml in Dulbecco’s phosphate-
buffered saline (PBS) for 1 h at 37°C and then blocked with 2% bovine serum
albumin in PBS for 0.5 h at room temperature. After blocking, membranes were
rinsed with PBS for 5 min and 500 ml of DMEM was added to the lower chamber.
Transfected cells (105) were plated into each chamber in DMEM and allowed to
migrate through the pores for 2 h. Cells that migrated through the membrane
were detected by staining for actin, by GFP fluorescence or, in the case of cells
expressing myc-tagged dominant negative constructs of Rac1 and Cdc42, by
immunostaining for myc.
Immunoprecipitation and immunoblotting. HEK293 or NIH 3T3 cells were
washed with PBS and lysed in modified RIPA buffer (25 mM Tris [pH 7.4], 150
mM NaCl, 10 mM MgCl2, 2 mM EGTA, 0.02% sodium dodecyl sulfate [SDS],
0.2% deoxycholate, 1% NP-40) for 5 min on ice. Lysates were clarified by
centrifugation at 12,000 3 g for 10 min. Protein concentrations were measured
using the Coomassie protein assay reagent, with bovine serum albumin as a
standard, following the manufacturer’s instructions (Pierce, Rockford, Ill.). Vav2
was immunoprecipitated from cell lysates (1 mg of protein), using 2 ml of Vav2
rabbit antiserum. Immunoprecipitates were collected by incubating with protein
A-Sepharose (Sigma, St. Louis, Mo.) for 1 h at 4°C. The immunoprecipitates
were washed three times with modified RIPA buffer and bound proteins were
eluted by boiling in SDS-polyacrylamide gel electrophoresis sample buffer. Im-
munoprecipitates and cell lysates were analyzed on SDS-polyacrylamide gels and
then transferred to nitrocellulose membranes. Blotting was performed as de-
scribed previously. Peroxidase-conjugated secondary antibodies were from
Chemicon (Temecula, Calif.). Blots were developed using SuperSignal Substrate
for Western blotting (Pierce) and then exposed to Kodak Scientific Image film.
Activity assays for Rac1, Cdc42, and RhoA. The assay of Rac1 activity was
performed as previously described (4) with some modifications. Cells were first
rinsed once with 20 mM HEPES, pH 7.4, and 150 mM NaCl and then lysed in
RIPA buffer with 500 mM NaCl and protease inhibitors. GTP-bound Rac1 (i.e.,
activated Rac1) was affinity precipitated from cell lysates (350 to 500 mg of
protein) using an immobilized GST fusion construct of the Rac1 binding domain
of murine p65Pak (the p21Rac binding domain [PBD]) that binds to Rac1-GTP
but not to Rac1-GDP (3). The GST-PBD construct was kindly provided by R. A.
Cerione and S. Bagrodia (Cornell University, Ithaca, N.Y.). Rac1 that sedi-
mented with the GST-PBD beads was separated using SDS-polyacrylamide gel
electrophoresis transferred to polyvinylidene difluoride membrane and blotted
with an antibody against Rac1 (Transduction Labs, San Diego, Calif.). Cdc42-
GTP binds to the same PBD construct (3) and so the same assay was used to
measure Cdc42 activity, except that the blots were probed with an antibody
against Cdc42 (Transduction Labs). Essentially the same assay was used to
measure RhoA-GTP, except for these assays, the RhoA binding domain (RBD)
of Rhotekin (40) was used as a GST construct (kindly provided by L. Petch,
University of North Carolina at Chapel Hill). RhoA that sedimented with the
GST-RBD beads was detected with an antibody against RhoA (Transduction
Labs).
Quantitation of bands on immunoblots was performed using Metamorph soft-
ware (Universal Imaging, Westchester, Pa.). Films were scanned with a ScanJet
6100C film scanner, and the images were imported into Metamorph for quanti-
tation. For each pulldown assay, the level of GTPase sedimented was normalized
relative to the amount of the GTPase in the cell lysate. This was done to avoid
errors arising from different levels of expression of the GTPases in different
samples.
For some experiments (see Fig. 8), quantitation of Rac1 activity was per-
formed using phosphorimager analysis of immunoblots. For these experiments,
blots were developed using enhanced chemifluorescence (Amersham Life Sci-
ences, Little Chalfont, Buckinghamshire, United Kingdom). Blots were scanned
with a Storm phosphorimager under blue fluorescence. Quantitation of band
intensities was performed using ImageQuant. Statistical significance was calcu-
lated using the Student two-sample t test. P values of ,0.05 were considered
significant.
Immunofluorescence. Cells were processed for immunofluorescence micros-
copy as previously described (30). Briefly, cells were fixed in 3.7% formaldehyde
in PBS for 10 min, rinsed in TBS at pH 7.6 for 3 min, and then permeabilized for
8 min in TBS containing 0.5% Triton X-100. Expression of the various Vav2-
GFP constructs was determined by GFP fluorescence. Actin was visualized using
phalloidin labeled with Texas red (Molecular Probes, Eugene, Oreg.). Micros-
copy was performed on a Zeiss Axiophot microscope. Images were acquired with
a MicroMAX 5 MHz cooled charge-coupled device camera (Princeton Instru-
ment, Trenton, N.J.) and processed using Metamorph Image software (Universal
Imaging).
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RESULTS
Vav2 is tyrosine phosphorylated in response to growth fac-
tors but not in response to extracellular matrix. Integrin-
mediated cell adhesion results in tyrosine phosphorylation of
several signaling molecules, such as FAK, paxillin, and
p130Cas (2, 7, 13, 47). To determine if Vav2 becomes tyrosine
phosphorylated during integrin-mediated adhesion, Vav2 was
immunoprecipitated from serum-starved HEK293 cells that
were either held in suspension or allowed to attach and spread
on fibronectin for times of 10, 20, 30, or 60 min. The immu-
noprecipitated Vav2 was analyzed for the presence of phos-
photyrosine by immunoblotting (Fig. 1a). Low levels of phos-
photyrosine were detected in Vav2 from cells in suspension
and those adhering to fibronectin at all time points, but no
increase in Vav2 tyrosine phosphorylation was detected in re-
sponse to adhesion. Similarly, Vav2 tyrosine phosphorylation
was not observed in response to adhesion to collagen (data not
shown). In addition, no stimulation of Vav2 tyrosine phosphor-
ylation was observed when NIH 3T3 cells were plated on fi-
bronectin (data not shown).
Exploring other factors that might stimulate the tyrosine
phosphorylation of Vav2, serum-starved, adherent HEK293
cells were treated with EGF (100 ng/ml) for 0, 5, 10, 20, 30, 40,
or 60 min, and Vav2 was immunoprecipitated and analyzed by
blotting with antiphosphotyrosine (Fig. 1b). Under these con-
ditions, Vav2 revealed robust tyrosine phosphorylation, which
had already peaked by 5 min of stimulation with EGF. Densi-
tometric analysis of the phosphotyrosine blot revealed that the
level of phosphotyrosine in Vav2 was elevated approximately
sevenfold at the 5-min time point. At 60 min of EGF stimula-
tion, the level of phosphotyrosine in Vav2 had decreased to
twofold above the unstimulated level. To examine whether
other growth factors also stimulated Vav2 tyrosine phosphor-
ylation, NIH 3T3 cells were treated with PDGF-BB (50 ng/ml),
and Vav2 was immunoprecipitated and analyzed for phospho-
tyrosine by blotting (Fig. 1c). Again, tyrosine phosphorylation
was observed in response to this growth factor (fourfold ele-
vation in phosphotyrosine at 10 min of PDGF treatment), but
the phosphorylation was more transient than that induced by
EGF, and by 20 min it had decreased to just twofold above the
background level. Previous work has demonstrated that the
exchange factor activity of Vav2 (like that of Vav1) is regulated
by tyrosine phosphorylation (46), suggesting that Vav2’s ex-
change factor activity is downstream of soluble growth factors
but not downstream of b1 integrin engagement. We also ex-
amined whether the tyrosine phosphorylation of Vav2 induced
by growth factors was affected by cell adhesion to ECM. We
observed that EGF treatment of either suspended or adherent
cells both resulted in elevated tyrosine phosphorylation of
Vav2 (data not shown).
Wild-type and N-terminally truncated Vav2 induce mem-
brane ruffling and lamellipodia in fibroblasts. In order to
FIG. 1. Vav2 is tyrosine phosphorylated in response to growth factors but not in response to adhesion to ECM. (a) Upper panel: antiphosphotyrosine blot of
endogenous Vav2 immunoprecipitated from HEK293 cells held in suspension (S) or plated on fibronectin (Fn) for 10, 20, 30, or 60 min. Bottom panel: the blot was
stripped and reprobed for Vav2 with an anti-Vav2 antibody to compare the amounts of Vav2 immunoprecipitated for each time point. (b) Upper panel: antiphos-
photyrosine blot of Vav2 immunoprecipitated from serum-starved HEK293 cells that were treated with EGF (100 ng/ml) for 0, 5, 10, 20, 30, 40, or 60 min. Bottom panel:
the amount of Vav2 protein immunoprecipitated was compared by stripping the blot and reprobing with anti-Vav2 antibody. (c) Vav2 is tyrosine phosphorylated in
response to PDGF-BB. NIH 3T3 cells were treated for 0, 10, and 20 min with PDGF-BB (50 ng/ml). Vav2 was immunoprecipitated and blotted for phosphotyrosine
(upper panel), and Vav2 (lower panel).
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study the activity of Vav2 in cells, we generated a set of Vav2
constructs (Fig. 2), each one fused to GFP at the carboxy
terminus so that the expression of the constructs could be
monitored in live cells. These constructs included wild-type
Vav2, a construct in which the amino-terminal calponin ho-
mology (CH) domain and acidic domain (AD) are deleted
(D184N Vav2), and a construct consisting of the carboxy-ter-
minal SH2 domain flanked by the two SH3 domains (SH3-
SH2-SH3). Previous work has shown that deletion of the ami-
no-terminal CH domain and AD results in a form of Vav2 that
is constitutively active in vitro with respect to exchange factor
activity and that expression of such mutants is a potent inducer
of transformation in NIH 3T3 cells (1, 45, 46).
To examine the effect of these GFP-tagged Vav2 constructs
on cell morphology, cytoskeletal organization, and cell migra-
tion, the constructs were expressed in a variety of cell types
using transient transfection. Expression of either wild-type
Vav2 or D184N resulted in a reorganization of actin in NIH
3T3 and BALB/c3T3 cells (Fig. 3). (These cell types were used
because of their well-spread morphology, prominent stress fi-
bers, and ability to develop easily visualized membrane ruffles.)
Both constructs induced extensive membrane ruffling and la-
mellipodial extension. In general, D184N Vav2 was more po-
tent and often generated broad lamellipodia that extended
around much of the cell margin (Fig. 3 E to H). Many cells
expressing wild-type Vav2 or D184N Vav2 revealed stress fi-
bers that were more prominent than the stress fibers of un-
transfected cells or cells transfected with GFP alone (Fig. 3A
and B). No significant effects on morphology or actin organi-
zation were observed in cells in which the SH3-SH2-SH3 con-
struct was expressed (data not shown). We examined the state
of tyrosine phosphorylation of the expressed wild-type and
D184N Vav2 constructs by immunoprecipitating these from
cell lysates using an antibody against GFP. Immunoblotting
these immunoprecipitates revealed that both the wild-type and
D184N Vav2-GFP constructs were tyrosine phosphorylated
(data not shown).
The above analysis was performed on transfected cells that
were maintained in the presence of serum. We wished to ex-
amine the effects of these Vav2 constructs on cells in the
absence of either serum or growth factors. For these experi-
ments, NIH 3T3 cells were transfected and after 24 h were
transferred to serum-free conditions for an additional 24 h
before fixing and staining for actin. Nontransfected, serum-
starved cells showed decreased stress fibers and no membrane
ruffling activity (Fig. 4). However, cells overexpressing either
wild-type Vav2 (Fig. 4A and B) or D184N Vav2 (Fig. 4C and
D) continued to reveal prominent stress fibers and membrane
ruffles under serum-free conditions.
Cell migration is induced by Vav2 and can be blocked by
N17Rac and N17Cdc42. The prominent membrane ruffling
displayed by cells in which wild-type Vav2 or D184N Vav2 was
expressed indicated that these cells might display enhanced
migratory behavior. To explore the effects of Vav2 on cell
migration, we used a Transwell assay, in which the lower sur-
face of a porous polycarbonate membrane was coated with
fibronectin and the number of cells migrating through the
membrane after 2 h under serum-free conditions was deter-
mined by counting. For these experiments, the D184N Vav2
construct was used because of its higher potency. Migration
was assayed using CHO cells because of their high transfection
efficiency and because their migratory activity is easily deter-
mined using Transwell filters. Expression of D184N Vav2 in
CHO cells resulted in an approximately twofold increase in the
number of cells migrating through the Transwell filter com-
pared with untransfected cells or cells expressing GFP only
(Fig. 5). To explore whether this stimulation of cell migration
involved Rac1 or Cdc42, cells were cotransfected with D184N
Vav2 and dominant negative versions of Rac1 (N17Rac1) or
Cdc42 (N17Cdc42). Coexpression of either N17Rac1 or
N17Cdc42 blocked the increase in migration induced by
D184N Vav2 (Fig. 5). In addition, cotransfection of N17Rac1
or N17Cdc42 blocked the morphological phenotype of prom-
inent membrane ruffles and lamellipodia in CHO cells express-
ing D184N Vav2 (Fig. 6). Coexpression of the dominant neg-
ative constructs did not alter the level of expression of D184N
Vav2 (data not shown).
Vav2 increases Rac1, Cdc42, and RhoA activity. The above
results suggest that Rac1, Cdc42, and RhoA are involved in the
Vav2-induced phenotype of increased migration and in the
morphological effects generated by Vav2 overexpression or
activation. However, the use of dominant negative Rho family
members is indirect. These dominant negative constructs work
by competing with the endogenous G proteins for binding to
exchange factors (17, 50). Many GEFs activate more than one
Rho family member (10, 49, 51); therefore, dominant negative
forms of these G proteins may block the activity of a related
but distinct family member. Indeed, this probably accounts for
the inhibition of membrane ruffling by dominant negative
N17Cdc42 noted above. Consequently, we wished to measure
directly the activity of Rac1, Cdc42, and RhoA in cells trans-
fected with our Vav2 constructs. Because of their high trans-
FIG. 2. Schematic representation of Vav2 fusion proteins used in this paper. Each construct was fused at the C terminus to GFP. The domains indicated are the
CH, AD, Dbl homology (DH), pleckstrin homology (PH), SH3, and SH2 domains. D184N is a constitutively active, amino-terminally truncated version of Vav2 that
lacks the CH domain and AD. The carboxy-terminal mutant contains only the SH2 domain flanked by the two SH3 domains.
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fection efficiency, CHO cells were used for these experiments.
Measuring the amount of GTP bound to Rho family proteins
has been difficult because of high intrinsic GTPase rates and
because antibodies against these proteins are generally not
good for immunoprecipitation. We have employed affinity pre-
cipitation assays to measure the amount of these proteins that
have GTP bound (4, 6, 40, 43). To measure the amounts of
active Rac1 and Cdc42, we used a GST construct of PAK3,
which selectively binds to the GTP-bound but not GDP-bound
forms of Rac1 and Cdc42 (3, 4). To measure the level of active
RhoA, we used a GST construct of Rhotekin, which selectively
binds to the GTP-bound form of RhoA but not the GDP-
bound form (40). Glutathione-Sepharose beads complexed to
the described GST fusion proteins were used to affinity pre-
cipitate GTP-bound Rac1, Cdc42, or RhoA. The amount of
active G protein was detected by blotting with antibodies to
Rac1, Cdc42, and RhoA.
Expression of D184N Vav2 in CHO cells resulted in elevated
levels of active Rac1, Cdc42, and RhoA compared with control
cells expressing GFP alone (Fig. 7). With RhoA and Rac1, the
level of increase was about 1.7-fold, whereas with Cdc42, the
increase in several experiments was greater, although more
variable (Fig. 7d). These experiments involved transient trans-
fection of D184N Vav2, and only about 30% of the cells on a
dish were transfected. Consequently, the level of active RhoA
and Rac1 in the cells expressing D184N Vav2 would have been
elevated approximately 2.5-fold above the level in untrans-
fected cells. For Cdc42, the level of activation would have been
still higher. We also investigated the effect of transfecting wild-
type Vav2 on Rac1 and RhoA activity and found that overex-
pression of Vav2 increased the level of activity of both of these
proteins, but to a lesser extent than D184N Vav2 (data not
shown). All the above experiments were conducted with cells
grown in the presence of serum. We were concerned that
factors present in serum, such as lysophosphatidic acid, would
activate RhoA (41) and that greater effects on RhoA activity
might be seen in the absence of serum. Consequently, we also
examined the effect of D184N Vav2 expression on RhoA ac-
tivity in serum-starved cells. However, this revealed essentially
equivalent levels of RhoA activation in response to D184N
Vav2 expression in the absence of serum as in the presence of
serum (data not shown).
Previous studies have demonstrated that growth factors such
as EGF and PDGF stimulate Rac activity (24, 35, 42). We have
FIG. 3. The effects of Vav2 transient expression on the actin cytoskeleton. NIH 3T3 cells (A to F) were transiently transfected with GFP alone (A and B), with
wild-type Vav2 as a GFP construct (C and D), or with the D184N Vav2-GFP (E and F). BALB/c3T3 cells (G and H) were transfected with D184N Vav2 as a GFP fusion
protein. Transfected cells were visualized for GFP (A, C, E, and G). The distribution of actin was visualized by staining with phalloidin conjugated with Texas red (B,
D, F, and H). Note that expression of both wild-type and D184N Vav2 induced prominent lamellipodia and membrane ruffles. Bar 5 20mm.
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shown here that these growth factors also result in the tyrosine
phosphorylation of Vav2 (Figure 1b and c), and previously
tyrosine phosphorylation of Vav2 has been shown to activate it
as an exchange factor (46). To determine whether Vav2 was
required for growth factor-mediated activation of Rac1, we
expressed the SH3-SH2-SH3 carboxy-terminal construct as a
putative dominant negative form of Vav2. HEK293 cells were
transfected with GFP alone or with the SH3-SH2-SH3 Vav2
C-terminal construct. The cells were stimulated with EGF for
20 min, and the level of active Rac1 was measured (Fig. 8). For
these experiments, quantitation was performed by phosphor-
imager analysis of the immunoblots. Stimulation of the cells
with EGF resulted in an approximately 1.8-fold elevation in
Rac1 activity. Expression of the C-terminal Vav2 construct
consistently reduced the level of EGF-stimulated Rac1 activity
to about 30% of the level achieved by EGF stimulation of cells
expressing GFP (P 5 0.03). Because only a fraction of the cells
were transfected with the Vav2 C terminus, these results sug-
gest that expression of this Vav2 construct blocked the eleva-
tion in Rac1 activity induced by EGF. This supports the idea
that EGF stimulates a rise in Rac1 activity, at least in part
through activation of endogenous Vav2.
DISCUSSION
At the outset of this work, we were interested in determining
whether the GEF Vav2 acts downstream of b1 integrin en-
gagement in nonhematopoietic cells. b1 integrins mediate the
adhesion of cells to many ECM proteins (27). During the
process of adhesion and spreading on ECM substrates, cells
extend filopodia and lamellipodia, and over a longer time
course they develop stress fibers. These cytoskeletal rearrange-
ments are regulated by Cdc42, Rac1, and RhoA, respectively,
three low-molecular-weight G proteins that belong to the Ras
FIG. 4. The effects of Vav2 transient expression on actin organization in serum-starved cells. NIH 3T3 cells were transiently transfected with either wild-type
Vav2-GFP (A and B) or D184N Vav2-GFP (C, D). After 24 hours in the presence of serum, the cells were starved for a further 24 hours before fixation and staining
for actin. The transfected cells are shown in A and C, the organization of actin is shown in B and D. Bar 5 20 mm.
FIG. 5. Constitutively activated Vav2 induced an increase in cell migration
that was inhibited by dominant negative forms of Rac1 and Cdc42. Transwell
assays were performed on CHO cells transiently transfected with GFP alone,
D184N Vav2-GFP alone, or D184N Vav2-GFP cotransfected with myc-tagged
N17Rac1 or N17Cdc42. Cells were plated on the Transwell membrane in serum-
free medium in the absence of ECM and growth factors. The underside of the
Transwell membrane was coated with fibronectin (10 mg/ml). Cells migrating
through the membrane in a 2-h period were counted. The bar graph represents
three separate experiments (error bars, standard error of the mean). For the
inhibition of migration by N17Rac1, P 5 0.015. For the inhibition of migration
by N17Cdc42, P 5 0.005.
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superfamily (22, 50). The activity of these proteins can be
stimulated by many soluble factors, and recent work has shown
that b1 integrin-mediated adhesion itself stimulates rapid ac-
tivation of Cdc42 and Rac1 (14, 38) and a slower activation of
RhoA (5, 40). The pathway from b1 integrins to the activation
of these Rho family proteins has not been determined, but it is
likely to involve activation of GEFs or inhibition of GAPs.
Previous work has demonstrated a link between multiple
integrins and Vav1, a Rho family GEF restricted to hemato-
poietic cells. Vav1 becomes activated in response to tyrosine
phosphorylation (16, 23). Platelet adhesion to fibrinogen via
the integrin aIIbb3, or to collagen or fibronectin via b1 inte-
grins leads to a rapid tyrosine phosphorylation of Vav1 (12).
Expression of aIIbb3 and Vav1 in CHO cells, together with the
hematopoietic tyrosine kinase, Syk, led to activation of Vav1
when these cells adhered to fibrinogen via the expressed
aIIbb3 (31). In addition, these cells developed a pronounced
Rac1 phenotype of extensive lamellipodia and ruffling mem-
branes. This work led us to investigate whether the widely
distributed Vav family member Vav2 might function as a GEF
downstream from b1 integrin engagement in nonhematopoi-
etic cells. Vav2 shares extensive homology with Vav1, including
the same domain structure (9, 45). Tyrosine phosphorylation
has been shown to activate Vav2 as it does Vav1 (46); there-
fore, we used tyrosine phosphorylation as an indicator of Vav2
activity. Contrary to our expectations, we were unable to detect
elevated phosphotyrosine in Vav2 in cells plated on fibronectin
or collagen, both of which are ligands for b1 integrins. These
results indicated that Vav2 is unlikely to act as a Rho family
GEF downstream of integrins in the fibroblastic and epithelial
cells that we have examined. We began to explore other agents
that might promote Vav2 tyrosine phosphorylation and hence
activation. We found that the growth factors EGF and PDGF
resulted in a rapid but transient tyrosine phosphorylation of
this exchange factor. Similarly, Moores and colleagues have
also found that Vav2 is tyrosine phosphorylated in response to
EGF and PDGF, but not tyrosine phosphorylated in response
to integrin-mediated adhesion (31a). After completion of our
work, the association of tyrosine phosphorylated Vav2 with the
EGF and PDGF receptors was described (37).
We have been interested in the targets of Vav2 activity.
Initial studies measuring GEF activity in vitro indicated that
Vav2 differed from Vav1 with respect to its targets in the Rho
family (46). Vav1 has been shown to act on Rac1, Cdc42, and
FIG. 6. Effect of coexpressing dominant negative Cdc42 and Rac1 on the morphology of cells expressing constitutively active Vav2. CHO cells were transfected with
D184N Vav2-GFP either alone (A and B) or cotransfected with myc-tagged N17Cdc42 (C to E) or myc-tagged N17Rac1 (F to H). Actin was visualized by staining with
rhodamine-phalloidin (A, C, and F). Cells expressing D184N Vav2-GFP were visualized by GFP fluorescence (B, D, and G). Cells expressing the myc-tagged constructs
were visualized by immunofluorescence (E and H). Bar 5 20 mm.
7166 LIU AND BURRIDGE MOL. CELL. BIOL.
RhoA (16, 23), whereas Vav2 was noted to act on RhoA and
RhoG, but not on Rac1 or Cdc42 (46). A different result,
however, has been obtained from Abe et al., who have found
that Vav2 has exchange factor activity for Rac1, Cdc42, and
RhoA in vitro (1). To explore the activity of Vav2 in cells, we
have expressed a GFP-tagged construct of wild-type Vav2, as
well as a GFP-tagged, amino-terminally truncated version of
the protein. Amino-terminal truncation of many GEFs renders
them constitutively active and oncogenic (10, 51), and this is
also true with Vav1 and Vav2 (1, 9, 46). We have examined
both the actin cytoskeletal organizations of cells overexpress-
ing these Vav2 constructs and measured the level of active
Rac1, Cdc42, and RhoA. Morphologically, cells expressing
Vav2 or its oncogenic, truncated form revealed both a Rac1
and a RhoA phenotype. The cells displayed extensive lamelli-
podia and ruffling membranes but also had prominent stress
fibers. In addition, these cells showed enhanced cell migration.
We found that the increased migration was inhibited by coex-
pression of dominant negative forms of Rac1 or Cdc42. These
dominant negative constructs also inhibited the prominent
membrane ruffling induced in cells expressing the constitu-
tively active form of Vav2.
In order to measure the level of active Rac1, Cdc42, and
FIG. 7. Vav2 expression elevates the activity of Rac1, Cdc42, and RhoA in cells. (a to c) Blots with anti-Rac1, Cdc42, and RhoA are shown, respectively. In each
case, the top panels show immunoblots of the protein that was sedimented by either the GST-PBD beads (i.e., Rac1-GTP or Cdc42-GTP) or the GST-RBD beads (i.e.,
RhoA-GTP) after incubation with lysates from cells transfected with GFP or D184N Vav2. The bottom panels show blots of the corresponding cell lysates. (d) Graphical
representation of relative activity of RhoA, Rac1, and Cdc42 in cells transfected with D184N Vav2. The activity level of RhoA, Rac1, and Cdc42 in cells transfected
with GFP was set at 1. Each bar represents the mean of three separate experiments (error bars, standard error of the mean). For the increase in RhoA and Rac activity,
P , 0.001. For the increase in Cdc42 activity, P 5 0.03.
FIG. 8. Expression of the carboxy terminus of Vav2 decreases EGF-induced
Rac1 activation. HEK293 cells were either untreated (2) or stimulated for 20 min
with EGF (100 ng/ml), and the level of active Rac1 was measured using sedi-
mentation with GST-PBD beads, blotting for Rac1, and phosphorimager anal-
ysis. The level of Rac1 activity in unstimulated cells was set at 100%. Comparison
of EGF-treated cells with unstimulated cells indicated an increase in Rac1
activity of approximately 1.8-fold (P 5 0.01). Expression of the Vav2 C-terminal
construct compared with expression of GFP decreased the level of Rac1 activity
in EGF-stimulated cells by approximately 30% (P 5 0.03). The data were com-
piled from four separate experiments. Error bars, standard error of the mean.
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RhoA, we have used affinity precipitation assays in which only
the GTP-bound forms of these proteins are sedimented by
binding to immobilized effector fusion proteins (4, 6, 40, 43).
Expression of these Vav2 constructs, particularly the amino-
terminally truncated form, resulted in elevated levels of Rac1,
Cdc42, and RhoA. These results are consistent with the mixed
Rac1 and RhoA phenotypes, i.e., with cells exhibiting promi-
nent ruffling membranes and also stress fibers. In general, we
did not observe an obvious Cdc42 morphological phenotype,
but the development of filopodia is often obscured by Rac1
activation, as filopodia become engulfed by lamellipodia and
membrane ruffles. Our results indicate that Vav2 activates
Rac1, Cdc42, and RhoA. Although this appears to differ from
the results of Schuebel et al. (46), who noted Vav2 activating
RhoA and RhoG in vitro but not Rac1 or Cdc42, it should be
noted that RhoG has been implicated in downstream activa-
tion of both Rac1 and Cdc42 (19). At present, we cannot say
whether the elevation of Rac1 and Cdc42 activity in cells over-
expressing Vav2 is due to a direct activation of these proteins
by Vav2 or is indirect and mediated by Vav2 acting on RhoG.
The tyrosine phosphorylation of Vav2 in response to stim-
ulating cells with EGF or PDGF suggests that it contributes to
Rac1 activity induced by these growth factors. Consistent with
this possibility, we found that expression of a carboxy-terminal
fragment of Vav2, which is predicted to compete with Vav2 for
interactions mediated via its SH3 and SH2 domains, decreased
the level of active Rac1 in cells stimulated with EGF (Fig. 8).
Similarly, in preliminary studies, we have noted that expression
of this C-terminal construct of Vav2 decreases Rac1 activity in
cells stimulated with PDGF (data not shown). Previous work,
however, has implicated Sos1 (32) and Sos1 complexed with
Eps8 and E3b1/Abi-1 (48) in the elevation of Rac1-GTP levels
downstream from receptor tyrosine kinases. It seems likely that
there are multiple pathways that lead from receptor tyrosine
kinases to Rac1 activation. In future work, it will be important
to compare the relative contributions of these and other GEFs
to the activation of Rho family proteins following cell stimu-
lation by growth factors.
Although our data demonstrate a role for Vav2 in growth
factor signaling to the cytoskeleton, the morphological pheno-
type of cells expressing activated Vav2 differs from that of
growth factor-stimulated cells. Cells overexpressing either full-
length or activated Vav2 display both extensive membrane
ruffles and increased stress fibers, indicative of a combination
of Rac1 and RhoA activation. In contrast, growth factors, such
as EGF and PDGF, rapidly induce membrane ruffling, but this
is accompanied by a loss of stress fibers and focal adhesions
(39, 42, 52). In some situations, this initial induction of mem-
brane ruffles in response to growth factors is followed by a
slower development of stress fibers (42). It is possible that the
function of Vav2 downstream from growth factor receptors is
to mediate the second phase of actin rearrangements in which
both membrane ruffles and stress fibers coexist. However, the
time course of Vav2 tyrosine phosphorylation in response to
growth factors is rapid and would be expected to result in an
immediate stimulation of both Rac1 and RhoA activity. An
alternative explanation is that, coincident with the initial acti-
vation of Vav2 by growth factors, a Rho GAP is simultaneously
activated and that this antagonizes RhoA activation. Previous
studies have indeed provided evidence for activation of
p190RhoGAP in response to EGF stimulation (11). One scenario
that we can envisage is a biphasic response to growth factor
stimulation, in which transient activation of p190RhoGAP is
coupled with a more sustained activation of Vav2. This would
result first in a decrease in RhoA activity that would be fol-
lowed by an increase with time. Such a response may be im-
portant in cell migration, a process that is triggered by growth
factors like PDGF and EGF. Evidence has been presented that
too-strong adhesion, such as that provided by focal adhesions,
can antagonize cell migration (26). The disassembly of stress
fibers and focal adhesions induced by growth factors has been
suggested to remove a brake that would otherwise retard mi-
gration. However, recent work has established that, while too
much RhoA activity inhibits migration, some RhoA activity is
necessary (34). Consequently, the activation of Vav2 by EGF
and PDGF may contribute to cell migration not only by acti-
vating Rac1 and Cdc42, but also by activating RhoA.
Vav2 contains many domains involved in binding other com-
ponents. It seems likely that its interactions with other com-
ponents will be important in regulating its activity in various
situations. A goal for the future will be to identify these inter-
actions and to determine how these interactions affect Vav2
activity and contribute to regulating complex events such as
cell migration.
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